Practical Management of Adverse Events in Multiple Myeloma: Can Therapy Be Attenuated in Older Patients?
Treatment Toxicity Management in Elderly With Multiple Myeloma
A Palumbo, MV Mateos, S Bringhen, JF San Miguel
Yes
20110601
2011 Jul 1
Blood Rev
Practical Management of Adverse Events in Multiple Myeloma: Can Therapy Be Attenuated in Older Patients?
Blood Rev. 2011 Jul 1;25(4):181-191, A Palumbo, MV Mateos, S Bringhen, JF San Miguel
Abstract
Abstract
The current standard of care for elderly patients with newly diagnosed multiple myeloma is melphalan and prednisone (MP) in combination with either bortezomib (VMP) or thalidomide (MPT), with lenalidomide plus dexamethasone increasingly being employed. The addition of bortezomib or thalidomide to the established MP regimen significantly improves outcomes and prolongs survival in elderly and transplant-ineligible patients. However, these benefits are accompanied by increases in treatment-related adverse...
